GlobalData on MSN4d
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m
Daiichi Sankyo buys solid tumour ADC from Glycotope for $132.5m Daiichi Sankyo has finalised the acquisition of intellectual ...
FiercePharma1d
Fierce Pharma Asia—AbbVie's $1B pact with Simcere; Takeda's launch map; Samsung Bio's growth plans
As the J.P. Morgan Healthcare Conference started in San Francisco on Monday, AbbVie linked up with Simcere with a $1 billion ...
Antibody Drug Conjugates Market Outlook 2025-2035, with Forecasts for Payload Type, Linker Type, Target Antigen and Applications
The "Antibody Drug Conjugates Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.World revenue for the Antibody Drug Conjugates Market is set to surpass US$16 billion in 2025 ...
Zacks.com on MSN12d
AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales. It has several candidates ...
Hosted on MSN1d
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...
Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Development | DelveInsight
The NSCLC pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical ...
Zacks.com on MSN2d
Merck Falls 9% in 3 Months: Buy, Hold or Sell the Stock?
Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...
Le Lézard5d
Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities
Schrödinger, Inc. today provided an update on its progress across the business in 2024 and announced its strategic priorities for 2025. "We are very proud of our accomplishments in 2024. We advanced ...
Le Lézard1d
DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
DATROWAY® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ ...
Pharmabiz22d
AstraZeneca, Daiichi Sankyo voluntarily withdrawn the MAA in the EU for datopotamab deruxtecan for patients with locally advanced or metastatic NSCLC
Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, datopotamab deruxtecan is one of six DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programmes in ...
AFP25d
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn
Designed using Daiichi Sankyo’s proprietary DXd ADC Technology, datopotamab deruxtecan is one of six DXd ADCs in the oncology pipeline of Daiichi Sankyo, and one of the most advanced programs in ...
pharmaphorum7d
Daiichi boosts cancer pipeline with $410m Ambit acquisition
Japan's Daiichi Sankyo has agreed a deal to buy Ambit Biosciences of the US for up to $410 million, bringing a new leukaemia candidate into its pipeline. The $15-per-share cash deal - which could ...